Literature DB >> 15952406

Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus.

M E Garay-Sevilla1, J C Regalado, J M Malacara, L E Nava, K Wróbel-Zasada, A Castro-Rivas, K Wróbel.   

Abstract

BACKGROUND: The accumulation of advanced glycation end products (AGEs) has a key role in the pathophysiology of diabetes complications. Comparison of AGEs measurement in serum, skin, saliva and urine has not been reported. AIMS: To compare AGEs in serum, skin, saliva and urine in patients with Type 2 diabetes mellitus, with complications at different stages.
MATERIALS AND METHODS: We examined 50 patients with Type 2 diabetes mellitus (40 women and 10 men) grouped according to the progression of neuropathy, nephropathy and retinopathy. The AGEs content in serum, skin, saliva and urine was measured by spectrofluorometry HPLC.
RESULTS: The patients had a mean age of 56.5 +/- 7.7 yr and 12.8 +/- 6.7 yr since diagnosis. AGEs in skin correlated with years since diagnosis (p = 0.0005). AGEs in serum, skin and saliva increased with the progression of complications, nevertheless, in urine a trend to diminution was found. In the group with end-stage renal disease (ESRD), AGEs in serum increased in greater proportion. In order to account for the decreased AGEs clearance, we corrected the values for creatinine levels, and AGEs in skin gave a better association with complications.
CONCLUSIONS: The AGEs measurement in skin, serum and saliva are useful to evaluate diabetes complications. AGEs in skin are associated with years since diagnosis of diabetes. Correction for renal function might discriminate AGEs in situ formation from accumulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952406     DOI: 10.1007/bf03345377

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Recent advances in understanding mechanisms and natural history of diabetic renal disease.

Authors:  G Viberti
Journal:  Diabetes Care       Date:  1988 Nov-Dec       Impact factor: 19.112

3.  Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy.

Authors:  Helen Vlassara; Weijing Cai; Jill Crandall; Teresia Goldberg; Robert Oberstein; Veronique Dardaine; Melpomeni Peppa; Elliot J Rayfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

4.  Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration.

Authors:  C He; J Sabol; T Mitsuhashi; H Vlassara
Journal:  Diabetes       Date:  1999-06       Impact factor: 9.461

Review 5.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

6.  Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus.

Authors:  T J Lyons; K E Bailie; D G Dyer; J A Dunn; J W Baynes
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

7.  Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse.

Authors:  Susanna M Hofmann; Heng-Jiang Dong; Zhu Li; Weijing Cai; Jennifer Altomonte; Swan N Thung; Feng Zeng; Edward A Fisher; Helen Vlassara
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461

Review 8.  Diabetic neuropathy in elderly patients. What can be done?

Authors:  J Belmin; P Valensi
Journal:  Drugs Aging       Date:  1996-06       Impact factor: 3.923

9.  Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes.

Authors:  P J Beisswenger; Z Makita; T J Curphey; L L Moore; S Jean; T Brinck-Johnsen; R Bucala; H Vlassara
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

10.  Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus.

Authors:  M E Garay-Sevilla; L E Nava; J M Malacara; K Wróbel; K Wróbel; U Pérez
Journal:  Diabetes Metab Res Rev       Date:  2000 Mar-Apr       Impact factor: 8.128

View more
  17 in total

Review 1.  Dietary advanced glycation end products and their role in health and disease.

Authors:  Jaime Uribarri; María Dolores del Castillo; María Pía de la Maza; Rosana Filip; Alejandro Gugliucci; Claudia Luevano-Contreras; Maciste H Macías-Cervantes; Deborah H Markowicz Bastos; Alejandra Medrano; Teresita Menini; Manuel Portero-Otin; Armando Rojas; Geni Rodrigues Sampaio; Kazimierz Wrobel; Katarzyna Wrobel; Ma Eugenia Garay-Sevilla
Journal:  Adv Nutr       Date:  2015-07-15       Impact factor: 8.701

2.  Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.

Authors:  Mattabhorn Phimphilai; Peraphan Pothacharoen; Prachya Kongtawelert; Nipon Chattipakorn
Journal:  J Bone Miner Metab       Date:  2016-11-21       Impact factor: 2.626

Review 3.  Advanced glycation end products and diabetic retinopathy.

Authors:  Yashodhara Sharma; Sandeep Saxena; Arvind Mishra; Anita Saxena; Shankar Madhav Natu
Journal:  J Ocul Biol Dis Infor       Date:  2013-04-19

4.  Diabetes-related molecular signatures in infrared spectra of human saliva.

Authors:  David A Scott; Diane E Renaud; Sathya Krishnasamy; Pinar Meriç; Nurcan Buduneli; Svetki Cetinkalp; Kan-Zhi Liu
Journal:  Diabetol Metab Syndr       Date:  2010-07-14       Impact factor: 3.320

5.  3-Deoxyglucosone: a potential glycating agent accountable for structural alteration in H3 histone protein through generation of different AGEs.

Authors:  Jalaluddin M Ashraf; Saheem Ahmad; Gulam Rabbani; Qambar Hasan; Arif Tasleem Jan; Eun Ju Lee; Rizwan Hasan Khan; Khursheed Alam; Inho Choi
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

6.  Pomegranate (Punicagranatum) juice decreases lipid peroxidation, but has no effect on plasma advanced glycated end-products in adults with type 2 diabetes: a randomized double-blind clinical trial.

Authors:  Golbon Sohrab; Pooneh Angoorani; Maryam Tohidi; Hadi Tabibi; Masoud Kimiagar; Javad Nasrollahzadeh
Journal:  Food Nutr Res       Date:  2015-09-08       Impact factor: 3.894

7.  Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Claudia Luévano-Contreras; Ma Eugenia Garay-Sevilla; Kazimierz Wrobel; Juan M Malacara; Katarzyna Wrobel
Journal:  J Clin Biochem Nutr       Date:  2012-12-06       Impact factor: 3.114

8.  The Rho/Rho-associated protein kinase inhibitor fasudil in the protection of endothelial cells against advanced glycation end products through the nuclear factor κB pathway.

Authors:  Yuyan Lu; Hailing Li; Weixia Jian; Jianhui Zhuang; Ke Wang; Wenhui Peng; Yawei Xu
Journal:  Exp Ther Med       Date:  2013-05-20       Impact factor: 2.447

9.  Advanced glycation end product-induced astrocytic differentiation of cultured neurospheres through inhibition of Notch-Hes1 pathway-mediated neurogenesis.

Authors:  Yijing Guo; Pin Wang; Haixia Sun; Rongrong Cai; Wenqing Xia; Shaohua Wang
Journal:  Int J Mol Sci       Date:  2013-12-23       Impact factor: 5.923

10.  Green synthesis of silver nanoparticles and characterization of their inhibitory effects on AGEs formation using biophysical techniques.

Authors:  Jalaluddin M Ashraf; Mohammad Azam Ansari; Haris M Khan; Mohammad A Alzohairy; Inho Choi
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.